Compare Amgen, Inc. (AMGN) vs Avient Corporation (AVNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Avient Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Avient Corporation trades at $36.03 (market cap $3.30B). The key difference: Amgen, Inc. is far larger — about 59.4× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| AMGN | AVNT | |
|---|---|---|
Market Cap | $196.12B | $3.30B |
Sector | Health | Technology |
52-Week High | $388.16 | $43.28 |
52-Week Low | $271.18 | $27.48 |
Enterprise Value | $241.41B | $4.80B |
Dividend Yield | 2.77% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Avient Corporation (AVNT) trades at $36.03, showing modest daily gains of 0.14%. The stock exhibits bearish technical signals with moving averages and ADX indicators pointing downward, though RSI levels remain neutral. Fundamentally, the company maintains stable revenue around $3.3 billion with improving profitability, as evidenced by three consecutive quarterly earnings beats. Recent product launches in barrier technology and dielectric thermoplastics demonstrate innovation in materials solutions.
Avient presents a mixed investment case with strong analyst support (60% buy ratings) offset by technical weakness. The company's consistent earnings performance and dividend payments provide stability, while competitive pressures and market volatility remain key risks. Near-term catalyst includes Q2 2026 earnings release on August 6, 2026, where the company faces expectations of $0.89 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
